Literature DB >> 26645984

Anatomical and ultrastructural study of PRAF2 expression in the mouse central nervous system.

Carmen Cifuentes-Diaz1, Stefano Marullo2, Stéphane Doly3.   

Abstract

Prenylated Rab acceptor family, member 2 (PRAF2) is a four transmembrane domain protein of 19 kDa that is highly expressed in particular areas of mammalian brains. PRAF2 is mostly found in the endoplasmic reticulum (ER) of neurons where it plays the role of gatekeeper for the GB1 subunit of the GABAB receptor, preventing its progression in the biosynthetic pathway in the absence of hetero-dimerization with the GB2 subunit. However, PRAF2 can interact with several receptors and immunofluorescence studies indicate that PRAF2 distribution is larger than the ER, suggesting additional biological functions. Here, we conducted an immuno-cytochemical study of PRAF2 distribution in mouse central nervous system (CNS) at anatomical, cellular and ultra-structural levels. PRAF2 appears widely expressed in various regions of mature CNS, such as the olfactory bulbs, cerebral cortex, amygdala, hippocampus, ventral tegmental area and spinal cord. Consistent with its regulatory role of GABAB receptors, PRAF2 was particularly abundant in brain regions known to express GB1 subunits. However, other brain areas where GB1 is expressed, such as basal ganglia, thalamus and hypothalamus, contain little or no PRAF2. In these areas, GB1 subunits might reach the cell surface of neurons independently of GB2 to exert biological functions distinct from those of GABAB receptors, or be regulated by other gatekeepers. Electron microscopy studies confirmed the localization of PRAF2 in the ER, but identified previously unappreciated localizations, in mitochondria, primary cilia and sub-synaptic region. These data indicate additional modes of GABAB regulation in specific brain areas and new biological functions of PRAF2.

Entities:  

Keywords:  CNS; Cilium; GABA(B) receptor; JM4; PRAF2; Synapse

Mesh:

Substances:

Year:  2015        PMID: 26645984     DOI: 10.1007/s00429-015-1159-8

Source DB:  PubMed          Journal:  Brain Struct Funct        ISSN: 1863-2653            Impact factor:   3.270


  3 in total

1.  Pharmacological chaperone-rescued cystic fibrosis CFTR-F508del mutant overcomes PRAF2-gated access to endoplasmic reticulum exit sites.

Authors:  Alexandre Hinzpeter; Stefano Marullo; Kusumika Saha; Benoit Chevalier; Stéphane Doly; Nesrine Baatallah; Thomas Guilbert; Iwona Pranke; Mark G H Scott; Hervé Enslen; Chiara Guerrera; Cérina Chuon; Aleksander Edelman; Isabelle Sermet-Gaudelus
Journal:  Cell Mol Life Sci       Date:  2022-09-27       Impact factor: 9.207

2.  PRAF2 overexpression predicts poor prognosis and promotes tumorigenesis in esophageal squamous cell carcinoma.

Authors:  Zhaoye Qian; Bin Wei; Yu Zhou; Qiuzi Wang; Jiru Wang; Yuan Sun; Yong Gao; Xiaofei Chen
Journal:  BMC Cancer       Date:  2019-06-14       Impact factor: 4.430

3.  PRAF2 expression indicates unfavorable clinical outcome in hepatocellular carcinoma.

Authors:  Chun-Hua Wang; Li-Li Liu; Ding-Zhun Liao; Mei-Fang Zhang; Jia Fu; Shi-Xun Lu; Shi-Lu Chen; Hong Wang; Shao-Hang Cai; Chris Zhiyi Zhang; Hui-Zhong Zhang; Jing-Ping Yun
Journal:  Cancer Manag Res       Date:  2018-07-25       Impact factor: 3.989

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.